PregnancyP-Beta-HNCT07493720
Comparison of Beta-hCG Levels When Using Venous Puncture Blood and Peripheral Finger Stick Blood
An observational study of Pregnancy, run by University of Nebraska at 1 site in United States.
Trial summary
The objective of his study is to quantitatively evaluate a patient's pregnancy status using their beta-hCG levels when using venipuncture blood vs peripheral blood. Read more about this study
- Who is it for?
- Ages 19 years and older, women only
- Conditions the study is for
- Pregnancy
- What is being tested?
- Beta-hCG
- How many people
- 40 participants
- Where
- 1 siteUnited States
- Study dates
- Sep 2026to Dec 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Study population: 19 years of age, positive pregnant status recorded in EMR, presenting to Nebraska Medicine OB/GYN clinic
Who may be able to join
- 19 years of age or older
- known pregnancy status either via urine, serum, or imaging results
- current patient of the Nebraska Medicine OB/GYN clinic
Who cannot join
- No meeting the inclusion criteria
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
University of Nebraska Medical Center
Omaha, Nebraska, 68198-1150
Thanh Nguyen, 4025597884, thang.nguyen@unmc.edu
About this study
The objective of his study is to quantitatively evaluate a patient's pregnancy status using their beta-hCG levels when using venipuncture blood vs peripheral blood.
Read the detailed description
The objective of his study is to quantitatively evaluate a patient's pregnancy status using their beta-hCG levels when using venipuncture blood vs peripheral blood. This data will help the investigator compare trending levels of beta-hCG levels in pregnant patients between venous blood vs peripheral blood which may help determine levels at which the peripheral blood may no longer be detectable on a POC pregnancy test.
- Conditions
- Pregnancy
- Being tested
- Beta-hCG
- Keywords
- pregnancy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Beta-hCGDiagnostic test
Enrolled participants will provide 2 serum specimens (venipuncture and peripheral finger stick) for beta-hCG testing
| Study group | Role | What they receive |
|---|---|---|
| Cohort 1 | 19 years of age or older, positive pregnancy status Receives: Diagnostic Test: Beta-hCG |
What is being measured
The primary outcome is the main question the study is designed to answer.
Beta-hCG value
Venipuncture and peripheral finger stick serum will be tested for beta-hCG levels.
Measured: Day 1
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Mar 2026
- Study startSep 2026 (estimated)
- Primary completionDec 2026 (estimated)
- Study completionDec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for PregnancyStudies of the same condition, open and under way.
- More trials run by University of NebraskaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Nebraska
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Thanh Nguyen, University of Nebraska
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07493720
- Sponsor's protocol ID
- 0843-25-EP
- Acronym
- P-Beta-H
- Status last verified
- Oct 2026
- First submitted
- 19 Mar 2026
- Last updated
- 27 Oct 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Publications
Fromm C, Likourezos A, Haines L, Khan AN, Williams J, Berezow J. Substituting whole blood for urine in a bedside pregnancy test. J Emerg Med. 2012 Sep;43(3):478-82. doi: 10.1016/j.jemermed.2011.05.028. Epub 2011 Aug 27.
PubMed 21875776
Study at a glance
From the registry record, last updated by the sponsor on 27 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison of Beta-hCG Levels When Using Venous Puncture Blood and Peripheral Finger Stick Blood
- ClinicalTrials.gov ID
- NCT07493720
- Acronym / sponsor ID
- P-Beta-H / 0843-25-EP
- Conditions
- Pregnancy
- Keywords
- pregnancy
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- University of NebraskaUniversity, hospital or other
- Study start
- Sep 2026 (estimated)
- Primary completion
- Dec 2026 (estimated)
- Study completion
- Dec 2026 (estimated)
- First posted
- 25 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of his study is to quantitatively evaluate a patient's pregnancy status using their beta-hCG levels when using venipuncture blood vs peripheral blood.
Detailed description
The objective of his study is to quantitatively evaluate a patient's pregnancy status using their beta-hCG levels when using venipuncture blood vs peripheral blood. This data will help the investigator compare trending levels of beta-hCG levels in pregnant patients between venous blood vs peripheral blood which may help determine levels at which the peripheral blood may no longer be detectable on a POC pregnancy test.
Study design
- Observational model
- Other
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Cohort 1 | – | Diagnostic Test: Beta-hCG19 years of age or older, positive pregnancy status |
Who may qualify
- Ages
- 19 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- 19 years of age, positive pregnant status recorded in EMR, presenting to Nebraska Medicine OB/GYN clinic
Key inclusion criteria (3 listed)
- 19 years of age or older
- known pregnancy status either via urine, serum, or imaging results
- current patient of the Nebraska Medicine OB/GYN clinic
Key exclusion criteria (1 listed)
- No meeting the inclusion criteria
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Beta-hCGEnrolled participants will provide 2 serum specimens (venipuncture and peripheral finger stick) for beta-hCG testing | Diagnostic test | Cohort 1 |
Primary outcome
Beta-hCG value
Time frame: Day 1
Venipuncture and peripheral finger stick serum will be tested for beta-hCG levels.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Oct 2026.
- Results publication: PubMed 21875776Fromm C, Likourezos A, Haines L, Khan AN, Williams J, Berezow J. Substituting whole blood for urine in a bedside pregnancy test. J Emerg Med. 2012 Sep;43(3):478-82. doi: 10.1016/j.jemermed.2011.05.028. Epub 2011 Aug 27.
- Individual participant dataSharing planned: No
Related trials for Pregnancy
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
Population Pharmacokinetics of Temocillin in Acute Enterobacterial Pyelonephritis in Children
Pyelonephritis
Active, not recruitingPhase 3
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
Carcinoma, Renal Cell
Recruiting
Safety and Performance of UCon Patch Electrode
Urinary Incontinence, Urinary Incontinence, Urge
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Pregnancy, run by University of Nebraska at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 27 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Thanh Nguyen, PhD (14025597884, thang.nguyen@unmc.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Beta-hCG value (time frame: Day 1). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07493720, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Oct 2026.